Standard titration schedule, injection protocol, and plateau management strategies
Semaglutide (the active ingredient in Ozempic and Wegovy) is a GLP-1 receptor agonist that has demonstrated significant weight loss in clinical trials. This guide covers the titration schedule used in research and clinical contexts, injection protocols, and strategies for managing dose-related side effects and weight loss plateaus.
Semaglutide is always started at a low dose and titrated upward to minimize GI side effects. The standard schedule used in clinical trials (STEP program): Weeks 1–4: 0.25 mg/week. Weeks 5–8: 0.5 mg/week. Weeks 9–12: 1.0 mg/week. Weeks 13–16: 1.7 mg/week. Week 17+: 2.4 mg/week (maintenance). Many researchers use a slower titration (4–8 weeks per step) to minimize nausea and GI distress.
Semaglutide is administered via subcutaneous injection once weekly. Injection sites: abdomen, thigh, or upper arm. Rotate injection sites each week. Inject on the same day each week for consistent plasma levels. Reconstituted semaglutide should be stored at 2–8°C and used within 28 days.
The STEP 1 trial (n=1961) showed 14.9% mean body weight reduction at 68 weeks with 2.4 mg/week semaglutide vs 2.4% with placebo. The STEP 4 trial demonstrated that discontinuing semaglutide results in weight regain, suggesting ongoing administration is required to maintain effects. Maximum weight loss typically occurs at 60–68 weeks.
Weight loss plateaus are common at 16–24 weeks. Strategies used in research contexts: ensure titration to full maintenance dose (2.4 mg/week), assess dietary adherence, consider combination with exercise protocols, evaluate whether dose reduction preceded plateau. Some protocols add a GIP agonist component (as in tirzepatide) for additional metabolic effect.
Tirzepatide (dual GIP/GLP-1 agonist) has shown superior weight loss in head-to-head trials (SURMOUNT-5): 20.2% vs 13.7% mean body weight reduction. However, semaglutide has a longer track record, more safety data, and is more widely available. See the Semaglutide vs Tirzepatide comparison for a full breakdown.
Clinical trials show an average of 14.9% body weight reduction at 68 weeks with 2.4 mg/week semaglutide (STEP 1 trial). Individual results vary significantly based on baseline weight, diet, and exercise.
Most people begin to see weight loss within 4–8 weeks of starting semaglutide. Maximum weight loss typically occurs at 60–68 weeks. The full titration to 2.4 mg/week takes approximately 16–17 weeks.
The STEP 4 trial showed that discontinuing semaglutide results in significant weight regain — approximately two-thirds of lost weight is regained within one year of stopping. This suggests ongoing administration is required to maintain weight loss effects.
Starting at a full maintenance dose (2.4 mg/week) without titration significantly increases the risk of severe nausea, vomiting, and GI distress. Titration is essential for tolerability and is standard in all clinical protocols.
Research Use Only
All content is for educational and research purposes. Not medical advice. Consult a qualified healthcare professional before considering any peptide protocol.
Parent Guide
Semaglutide Dosage GuideResearch Grade
Shop Purgo Labs
Use Code HEALTH for 15% OffMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.